An official website of the United States government
COVID-19 Severity and Mortality Among Chronic Liver Disease Patients: A Systematic Review and Meta-Analysis
SYSTEMATIC REVIEW — Volume 19 — August 25, 2022
PEER REVIEWED
Initially, we included 3,659 studies for our screening process. During our primary screening, we excluded 3,212 because they did not match our study eligibility criteria. We included 447 studies for our secondary screening. Of the 447 studies, 226 were excluded during our title and abstract screening. We retrieved 221 studies for full-text screening. We then excluded 97 studies because they reported findings only on acute liver injury, 30 because they did not match our study eligibility criteria, 28 because they had different diseases outcomes, and 26 because they did not compare the findings among COVID-19 patients. The reviewed was based on the remaining 40 studies.
Figure 1.
PRISMA flowchart showing the identification of studies for analysis of the association of chronic liver disease with severity of disease and mortality among COVID-19 patients. Abbreviation: PRISMA, Preferred Items for Systematic Reviews and Meta-Analyses.
The forest plot shows the chance of getting the severe form of COVID-19 is 2.44 times higher among CLD patients than among non-CLD patients.
Figure 2.
Forest plot showing the difference in severity between COVID-19 patients with and without CLD (N = 27). Abbreviation: CLD, chronic liver disease.
The forest plot shows that the mortality due to COVID-19 among CLD patients is 2.35 times higher than that among non-CLD patients.
Figure 3.
Forest plot showing the difference in mortality between COVID-19 patients with and without chronic liver disease (CLD) (N = 27).
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.